Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blueprint Medicines Corp.

www.blueprintmedicines.com

Latest From Blueprint Medicines Corp.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Approvals Business Strategies

EQRx Aims To Upend Industry’s Pricing Model, With Me-Too Drugs

With a $200m series A financing and an illustrious founding team, including Alexis Borisy and Peter Bach, EQRx plans to develop cheap me-too drugs. The start-up could pose a new threat to big pharma.

StartUps and SMEs Pricing Debate

Keeping Track: Ayvakit Approval, Keytruda Supplement, NME Submissions

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Blueprint Medicine Gains US Approval For First Drug, Precision Medicine Ayvakit

The FDA has granted full approval to the drug based on Phase I efficacy data and safety studies, reflecting lack of existing treatment options
Approvals FDA
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Blueprint Medicines Corp.
  • Senior Management
  • Jeffrey Albers, Pres. & CEO
    Mike Landsittel, CFO
    Marion Dorsch, PhD, CSO
    Anthony Boral, MD, PhD, CMO
    Kathryn Haviland, COO
  • Contact Info
  • Blueprint Medicines Corp.
    Phone: (617) 374-7580
    45 Sydney St.
    Ste. 200
    Cambridge, MA 02139
    USA
UsernamePublicRestriction

Register